The U.S. Food and Drug Administration is requiring updated labels for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) to warn about a rare eye condition that can cause sudden and potentially permanent vision loss.
Analysts note that for most patients the benefits of these medicines still outweigh the risks. Anyone taking a GLP-1 medicine who notices sudden blurred vision or loss of vision should seek urgent medical care, and should not stop treatment without talking to their doctor.
Source: MM+M / Reuters















